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Methods: Plasma-tau, CSF-tau, and P-tau were measured in 97 subjects, including elderly cogni-
tively normal controls (n 5 68) and patients with AD (n 5 29) recruited at the NYU Center
for Brain Health, with comprehensive neuropsychological and magnetic resonance imaging
evaluations.
Results: Plasma tau was higher in patients with AD than cognitively normal controls (P , .001,
area under the receiver operating characteristic curve 5 0.79) similarly to CSF tau and CSF
P-tau and was negatively correlated with cognition in AD. Plasma and CSF tau measures
were poorly correlated. Adding plasma tau to CSF tau or CSF P-tau significantly increased
the areas under the receiver operating characteristic curve from 0.80 and 0.82 to 0.87 and
0.88, respectively.
Discussion: Plasma tau is higher in AD independently fromCSF-tau. Importantly, adding plasma tau
to CSF tau or P-tau improves diagnostic accuracy, suggesting that plasma tau may represent a useful
biomarker for AD, especially when added to CSF tau measures.
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Tau is a microtubule-associated protein that is highly
expressed in the brain and functions as a structural element
in the axonal cytoskeleton [1,2]. In patients with
Alzheimer’s disease (AD), the neuronal and axonal
degeneration results in increased release of tau from the
microtubules. Furthermore, in pathological conditions
such as AD, chronic traumatic encephalopathy, or other
tauopathies, tau is truncated and/or phosphorylated
[3,4]. Phosphorylated forms of tau (P-tau) aggregate
in neurofibrillary tangles, contributing to cognitive
impairment [5,6]. Elevated cerebrospinal fluid (CSF) tau
and P-tau are established biomarkers for AD [7]. Plasma
has been proposed as an ideal biofluid for biomarker anal-
ysis, as it allows collection of samples with minimal burden
to the patients and facilitates longitudinal study designs [8].
However, until recently, AD biomarker measures were
restricted to the CSF. Recently, novel technologies, such as
single-molecule array (SIMOA), have enabled the detection
of tau at very low concentrations (picomolar) in the blood
[9]. Although plasma and CSF tau are not biomarkers spe-
cific for AD as CSF P-tau and blood tau has the potential to
derive from other sources in addition to neuronal tau [10,11],
work with ultrasensitive detection equipment suggests the
potential for plasma tau to serve as a biomarker for
neurodegeneration in AD as well as other neurological
disorders associated with brain trauma and tauopathies
[9,12–16]. Using the SIMOA technology, several studies
showed higher plasma tau levels in patients with
neurological disorders compared to cognitively normal
(NL) controls [9,15,17,18]. These results were promising,
although they typically showed a relatively high degree of
overlap in plasma tau concentrations between AD and
controls and weak correlations of plasma tau with CSF
total tau and P-tau levels in AD [19]. Little information is
currently available on the value of adding plasma tau to
CSF tau and CSF P-tau in AD biomarker panels in AD clin-
ical studies. Here, to explore the diagnostic value of plasma
tau and its usefulness in comparison to or in combination
with CSF tau and P-tau, we measured plasma and CSF tau
in 97 subjects including patients with AD and nondemented
controls recruited at the Center for Brain Health of NYU
Langone Medical Center. Moreover, we validated the agree-
ment of the different assays by comparing CSF samples run
with SIMOA and gold-standard ELISA assays and we exam-
ined the relationships of plasma tau with cognitive and struc-
tural magnetic resonance imaging (MRI) measures.2. Methods
2.1. Subjects
All subjects were recruited at the Center for Brain Health
of NYU School of Medicine (NYUSOM) and provided writ-
ten, informed consent to protocols approved by the NYU-
SOM Institutional Review Board (IRB) to participate inour National Institute of Health (NIH)–supported biofluids
and imaging studies of aging and AD. The patients with
mild AD enrolled were judged capable of understanding
the consent forms as determined by an independent clinician.
The standardized examinations were consistent with the
NIH-National Alzheimer Coordinating Center (NACC)
guidelines. The examinations included history, physical
and neurological assessments, psychiatric screens, clinical
laboratories, MRI, genetic testing, and neuropsychological
evaluations, which included Mini–Mental Status Examina-
tion [20] and Clinical Dementia Rating Scale [21] as well
as other elements of theAlzheimer’sDiseaseCenterUniform
Data Set Neuropsychological Test Battery [22]. Diagnosis of
normal or AD was made in accord with standard criteria
[23,24] by an experienced clinician based on progressive
memory and cognitive complaints corroborated by an
informant, clinically observed cognitive impairment as
previously described [25], and MRI to rule out other causes
of impairment. The patients with AD had Global Deteriora-
tion Scale scores of 4 or 5 and met DSM-IV [26] and
NINCDS-ADRDA [27] criteria for dementia. NL was
defined on the basis of consensus review of the aforemen-
tioned materials and achieved Global Deterioration Scale
scores of 1 or 2 [28], a Clinical Dementia Rating score of
0, withMini-Mental State Examination scores of 28 or higher
[20]. The norm-based neuropsychological battery of tests
was constructed as previously described [29]. Four cognitive
domains were assessed from the following tests: memory
(immediate and delayed recall of a paragraph [PARI and
PARD] and immediate and delayed recall of paired associ-
ates [PRDI and PRDD]), executive function (Wechsler Adult
Intelligence ScaleDigit Symbol Substitution), language (Ob-
ject Naming Test and Wechsler Adult Intelligence Scale vo-
cabulary), and visuospatial performance (Block Design
Test). The apolipoprotein E (APOE) genotypes were deter-
mined using published methods.2.2. Biofluid samples
CSF samples were processed as described previously
[25]. Briefly, after an overnight fast and a light breakfast
before 9 am, the lumbar puncture procedure began at 12
pm using a 25-G Sprotte needle guided by fluoroscopy.
15 mL of CSF was collected in three polypropylene tubes.
Samples were kept on ice for up to 1 h until centrifuged
for 10 min at 2000 g at 4C. 250 mL of samples was aliquoted
into 1-mL polypropylene tubes and stored at 280C until
thawed for the assays.
Blood samples were collected at the time of the lumbar
puncture and processed within 2 h from collection,
following consensus recommendations [30]. To obtain
plasma, 10 mL of blood was collected into EDTA tubes,
inverted 5 times immediately after collection, and then
centrifuged (10 minutes, 2,000g, 4C). All samples were
aliquoted (0.250 mL) into 1-mL polypropylene tubes and
stored at 280C. To avoid batching effects, experiments
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from all study groups once sufficient samples were
collected. Investigators running the experiments were blind
to study groups.2.3. Plasma total tau quantification
The plasma total tau assays were conducted at NYUSOM
in Dr. Fossati’s laboratory. Plasma total tau was measured
using SIMOA technology (Quanterix Corporation, MA), as
directed by the manufacturer. Briefly, the SIMOA enzyme-
linked immunoassay method uses a combination of a capture
antibody which recognizes amino acid 16-24 and a detector
antibody recognizing amino acid 218-222, with a digital
array technology that allows the measurement of total tau
in plasma or serum with a limit of detection of 0.019 pg/
mL. All assays were run in duplicate. Samples showing co-
efficients of variation higher than 20% were excluded and
reexamined.2.4. CSF tau and P-tau quantification
The CSF total tau and P-tau 181 assays were conducted at
the Sahlgrenska University Hospital in Sweden, as previ-
ously described [25]. Briefly, P-tau 181 was measured by a
gold-standard sandwich ELISA (INNOTEST, Fujirebio) us-
ing antibodies HT7 for capture and AT270 for detection and
a synthetic custom phosphopeptide phosphorylated threo-
nine 181 (P-tau181) as the standard calibrator [31]. Limit
of detection of this setting is 15.6 pg/mL. Intra-assay and
inter-assay coefficient variations are below 10%. The lower
limit of quantification was determined to be 25 pg/mL. CSF
total tau was measured using a similar gold-standard ELISA
protocol (INNOTEST, Fujirebio), based on using the mono-
clonal mid-domain antibodies AT120 for capture and HT7
and BT2 for detection [32]. Samples showing coefficients
of variation higher than 20% were remeasured. CSF tau
was also measured by Quanterix SIMOA at NYUSOM, as
described previously, in a subset of the normal subjects to
compare the 2 assays.2.5. Magnetic resonance imaging and processing
All MRI was performed on the 3T system (Siemens, Er-
langen, Germany). The imaging protocol consisted of
sagittal T1-weighted magnetization prepared rapid acquisi-
tion gradient echo. Intracranial volumes were estimated
using Statistical Parametric Mapping segmentation proced-
ure (SPM, ver.12, with new-segment extension). Cortical
thickness and hippocampal, CSF, and ventricular volumes
were obtained using the FreeSurfer (ver.6.0, MGH/HST
Martinos Center for Biomedical Imaging, USA). Hippocam-
pal volume was measured as Left Hippocampus 1 Right
Hippocampus/IntraCranialVol*100. Cortical thickness was
averaged with surface regions of interest, which were
defined by the Desikan-Killiany atlas [33].2.6. Statistical analyses
Demographic differences between diagnostic groups
were assessed using t-tests for continuous variables and c2
tests for nominal variables. The mean difference in plasma
tau between NL controls and patients with AD was tested
with a t-test and confirmed with a Mann-Whitney U test.
Binary logistic regression models were used to determine
the accuracy of plasma tau alone, as well as added to CSF P-
tau and total Tau, in categorizing patients with AD versus
NL controls after adjusting the models for age, APOE geno-
type, and sex as confounds. In the accompanying receiver
operating characteristic curve analyses, the sensitivity level
was set to 80% and differences in specificity levels between
the combined plasma and CSF tau and the individual mea-
sures were compared using the McNemar test for the com-
parison of paired binomial proportions. We used bootstrap
resampling with 2000 independent replications to obtain
the areas under the receiver operating characteristic curve
(AUCs) with a 95% CI, as well as the difference in AUCs be-
tween models (DAUC).
Spearman correlations were used within the NL and AD
groups separately to test for associations between plasma tau
and a cognitive test of delayed memory (delayed paragraph
recall) as well as the hippocampal volume and cortical thick-
ness measurements. All analyses were checked for viola-
tions of the model assumptions and any conflicts are
reported. The Box-Cox transformation procedure was used
to determine the most appropriate power transformation to
reconfigure values to a normal distribution. Differences in
variances were tested using Levene’s Test for Equality of
Variances, and the tests where equal variance was not
assumed were used when Levene’s Test was significant.
For all results, statistical significance was defined as a two-
sided P value of less than 5%. Statistical analyses were per-
formed using IBM SPSS (version 23.0).3. Results
3.1. Demographic and clinical characteristics
The demographic characteristics of the participants are
shown in Table 1. The AD group did not differ from the
NL group for gender, education, or race. The AD group
was on average 5 years older (P 5 .011) than the NL
group. As expected, the AD group had significantly higher
prevalence of APOE ε4 carriers than the NL group
(P , .018).3.2. Elevated plasma tau levels in AD
Significantly higher concentrations of plasma tau were
found in the AD group (n 5 29) compared with
age-matched NL controls (n 5 68) (mean [SD], 3.67
[1.06] vs. 2.74 [0.76] pg/mL, respectively; Effect
size 5 1.1; P , .001; Fig. 1A). This difference persisted
after corrections for plasma albumin concentrations (a
Table 1
Demographics
Characteristic AD (n 5 29) NL controls (n 5 68) P value
Age, mean (SD), y 72.81 (9.69) 67.71 (8.54) .011
Female, n (%) 19 (65.5) 44 (64.7) .939
Race, n (%) .116
Caucasian 23 (79.3) 59 (86.8)
Others 6 (20.7) 9 (13.2)
ApoE4 carriers, n (%) .018
ε42 17 (58.6) 44 (64.7)
ε4 1 12 (41.4) 24 (35.3)
Education, mean (SD), y 15.52 (3.23) 16.49 (2.17) .147
Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; NL,
elderly normal; SD, standard deviation; y, years.
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fects). Plasma tau did not correlate with age, whereas
CSF tau and CSF P-tau were weakly correlated with age
(Spearman r 5 0.28; P 5 .0045 for CSF tau and
r 5 0.21; P 5 .02 for CSF P-tau). Receiver operating
characteristic analyses for the classification of the AD
group and NL group showed similar AUCs for plasma
tau (AUC 5 0.79), CSF tau (AUC 5 0.80), and CSF P-
tau (AUC 5 0.82) (Fig. 1B).Fig. 1. Plasma tau, CSF tau, and P-tau levels in AD versusNLROC curves. (A) Pla
(NL) (Wilcoxon rank tests; effect size5 1.1; P5 .001). Bars represent median an
sification of the AD group for plasma tau and (AUC 5 0.79), CSF tau (AUC 5 0
controls and patients with AD similarly to plasma tau. Bars represent median and
spinal fluid; NL, cognitively normal; ROC, receiver operating characteristic.3.3. Relationship between CSFand plasma total tau levels
We explored the correlation between tau levels detected
in CSF and plasma in the same subjects. Results showed
weak correlations in the full cohort for plasma tau with
CSF tau (Spearman r 5 0.26; P 5 .009) and plasma tau
with CSF P-tau (Spearman r 5 0.29; P 5 .003). The signif-
icance of the association between plasma tau and both CSF
tau and P-tau was lost after correcting for diagnostic group in
linear regression models or in partial correlations (r5 0.12;
Sig 2-tailed5 0.25).When splitting the samples into the two
study groups (AD or NL), there was also no significant cor-
relation (in NL, CSF t-tau vs. plasma tau: Pearson r5 0.07,
Sig 2-tailed 5 0.55; Spearman r 5 0.05, Sig 2-
tailed 5 0.70; in NL, CSF P-tau vs. plasma tau: Pearson
r 5 0.13, Sig 2-tailed 5 0.29; Spearman r 5 0.13, Sig 2-
tailed 5 0.28; in AD, CSF t-tau vs. plasma tau: Pearson
r 5 0.20, Sig 2-tailed 5 0.33; Spearman r 5 0.25, Sig 2-
tailed 5 0.22; in AD, CSF P-tau vs. plasma tau: Pearson
r 5 0.15, Sig 2-tailed 5 0.47; Spearman r 5 0.14, Sig 2-
tailed 5 0.48) (Fig. 2A). Because CSF tau and CSF P-tau
were measured using ELISA (Fujirebio), whereas plasma
tau was measured with SIMOA (ELISA assays are not sen-
sitive enough to obtain plasma tau measurements), wesma total tau concentration is higher in patients with AD than control samples
d interquartile ranges. (B) ROC analyses show similar accuracy for the clas-
.80), and CSF P-tau (AUC 5 0.82). (C) CSF tau and P-tau discriminate NL
interquartile ranges. Abbreviations: AD, Alzheimer’s disease; CSF, cerebro-
Fig. 2. Correlation between plasma and CSF tau and correlation of SIMOAversus ELISA for CSF tau. (A) The significance of the association between plasma
tau and both CSF P-tau and tau is lost after correcting for diagnostic group in linear regression models or partial correlations (P. .05). The black line represents
the full group, the blue line represents NL, and the red line represents AD. (B) CSF tau measured by Simoa and ELISA in the same samples shows a strong
correlation (r 5 0.9517; P , .0001). Abbreviations: AD, Alzheimer’s disease; CSF, cerebrospinal fluid; NL, cognitively normal; P-tau, phospho-tau.
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ples, to explore the consistency between the two different as-
says. ELISA and SIMOA tau signals obtained in the same
CSF samples showed a very strong correlation
(r 5 0.9517; P , .0001; Fig. 2B), suggesting that the two
different assays perform very similarly when used in the
same medium.3.4. Correlations with MRI and cognitive measures
Plasma tau was negatively correlated with delayed para-
graph recall (PARD) (Spearman’s r 5 20.538; P 5 .012), a
measure of cognitive performance of Wechsler Memory
Scale-Revised test [29], in the AD group (Fig. 3). When
analyzing correlations of plasma tau with MRI measures,
we found that the correlation of plasma tau with hippocam-Fig. 3. Correlation between plasma tau and cognitive function (PARD) (A) and hip
tau and PARDwas found in the AD group (Spearman’s rho520.54; P5 .01), ind
tau. (B) The correlation between plasma tau and hippocampal volume did not reac
the AD group, suggesting smaller hippocampal volumes in subjects with higher pla
NL, cognitively normal; ROC, receiver operating characteristic; P-tau, phospho-tpal volume or cortical thickness did not reach significance in
the AD group (P. .12 and P. .26, respectively). There was
also no significant correlation of plasma tau, CSF tau, or CSF
P-tau with CSF volumes or ventricular volumes.3.5. Increased specificity for the combination of plasma
tau with either CSF tau or CSF P-tau
We also aimed to explore if the addition of plasma tau to
CSF tau or P-tau could improve the differentiation between
study groups. When adding plasma tau (AUC 0.79) to CSF
tau (AUC 0.80) or plasma tau to CSF P-tau (AUC 0.82),
we achieved significant increments, reaching AUCs of
0.87 and 0.88, respectively, for the combinations (Fig. 4),
indicating that the addition of plasma tau to both CSF
tau measures increased diagnostic accuracy for thepocampal volume (B): (A) A significant negative correlation between plasma
icating worse cognitive performance in patients with AD with higher plasma
h significance (P5 .12), although empirically showing a downward slope in
sma tau. Abbreviations: AD, Alzheimer’s disease; CSF, cerebrospinal fluid;
au; PARD, delayed paragraph recall.
Fig. 4. Increased specificity in AD diagnosis for the combination of plasma tau with CSF tau and P-tau measures. A significant improvement in area under the
ROC curve (AUC) is observed for the combination of CSF total tau with plasma tau (A) and CSF P-tau with plasma tau (B), respectively. (C) Table including
specificity (with sensitivity set at 80%), sensitivity (with specificity set at 80%), area under the ROC curve (AUC) for the single measurements and after the
addition of plasma tau to CSF tau and P-tau, and AUC for bootstrap resampling with 2000 independent replications. (D) Difference in AUCs between models
(DAUC). * indicates significant improvements (P , .05). Abbreviations: AD, Alzheimer’s disease; CSF, cerebrospinal fluid; NL, cognitively normal; ROC,
receiver operating characteristic; P-tau, phospho-tau.
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with 2000 independent replications to obtain the AUCs with
a 95% CI, as well as the difference in AUCs between models
(DAUC), the combined CSF and plasma models had a posi-
tive difference (i.e. higher predictive accuracy) in 99% of the
replications, and the 95% CI of the DAUC was greater than
0 for both combined models compared with plasma tau and
their respective CSF tau measures. We are therefore 95%
confident that the model including both CSF and plasma
tau yields a greater AUC than the AUC of either biomarker
alone (Fig. 4C, D).4. Discussion
Plasma tau has the potential to be among the first blood
biomarkers for neurological disorders to be implemented in
the clinical setting. The addition of plasma biomarkers
such as tau or neurofilament light to current CSF assays
for AD clinical trials [16,34,35] is currently under
consideration. In this study, we first replicated previous
findings showing that plasma tau levels are higher in
patients with AD compared with noncognitively impairedcontrols [9,15–17]. We found that plasma tau was able to
discriminate NL controls and patients with AD in our
cohort with a large effect size of 1.1. This significant
difference remained after we corrected for plasma
albumin, to rule out the possibility that patients with AD
may have lower blood volumes. Plasma tau alone
classified NL controls and patients with AD with a
similar accuracy when compared with the current gold-
standard CSF total tau or CSF P-tau assays. Second, we
corroborate that plasma tau seems independent of CSF
tau measures, as no significant correlations were detected
between plasma tau and CSF tau or P-tau [9,17]. Third,
we report the novel finding that adding plasma tau to
CSF tau or CSF P-tau measures increases the accuracy or
the differentiation of patients with AD versus NL
controls in our cohort.
A recent prospective study by Mattsson et al. using the
ADNI cohort showed that plasma tau differentiated AD
from controls, although there was a significant overlap
between study groups [17]. Our results are in line with
this work. Our study also confirmed a correlation
between plasma tau and cognitive dysfunction, which
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weak correlation of plasma tau with CSF tau and P-tau,
which was lost when correcting for study groups. The
loss of correlation between plasma and CSF tau values
when correcting or separating by the study groups is also
in line with previous findings [9,17], suggesting that
the higher mean value of CSF tau and plasma tau in
patients with AD compared with NL controls drives the
correlation when both groups are included without
correcting for diagnostic group. The lack of correlation
in the split groups could be also due to fact that the
smaller sample size lacks power to reach statistical
significance. The weak correlation between plasma and
CSF may also suggest potential differences in tau
fragments in the CSF and plasma compartments and/or
that these fragments would be differently recognized by
the SIMOA (plasma) and INNOTEST (CSF) antibody
combinations. However, in one of the first studies on
plasma tau in AD, an INNOTEST-like antibody combina-
tion (Tau5 for capture [similar to AT120 in INNOTEST]
and HT7 and BT2 [identical to INNOTEST]) was used
on SIMOA [9], suggesting that potential tau proteolysis
or other forms of clearance in plasma, as well as non-
central nervous system sources of tau, would affect the
two assay formats in a similar manner, which should be
explored in more detail.
In this work, we show that the SIMOA and ELISA assays
used perform with very high correlation in the same CSF
samples, suggesting that the lack of correlation between
plasma and CSF is driven mostly by the biological compart-
ment. A higher metabolism of tau by plasma proteases could
be one of the reasons of these differences. Owing to different
catabolic cleavage, the tau fragments present in CSF and
plasma will likely differ and smaller or different fragments
in plasma may remain undetected by the same immunoassay
that detects CSF fragments. The presence in blood of tau
derived from other sources different from brain cells could
also explain the lack of correlation with CSF [10,11]. The
expression of tau has been shown in platelets [10], as well
as in muscle, kidney, and other tissues (https://www.
proteinatlas.org/ENSG00000186868-MAPT/tissue), ex-
panding the pool of plasma tau to additional sources
compared with those for CSF tau. Moreover, differential
clearance pathways for interstitial fluid tau to the CSF or
plasma could contribute to the lack of correlation [36–38].
For example, interstitial fluid tau may be internalized by
glial cells or further catabolized before or after being
released to plasma [39]. Also, smaller fragments of tau
that are able to pass a dysfunctional blood brain barrier in
AD may not remain in the CSF for a sufficient time to be de-
tected, resulting in an increase in plasma tau fragments in pa-
tients with AD with a more damaged blood brain barrier.
Different antibody specificity and assay performance in
plasma versus CSF could also contribute to the weak corre-
lation between the tau levels in the two compartments.
Although this study cannot determine the causes of theweak correlation, these differences in assay results between
CSF and plasma could contribute to the better discrimination
of patients with AD and NL controls that we achieve adding
plasma tau to CSF tau measures.
Owing to the overlap between study groups (AD vs. NL)
and to the lack of a strong correlation with CSF tau discussed
previously, the validity of plasma tau alone as a biomarker
for AD has been debated [17,19]. However, recent studies
found that, in regression models adjusted for age, gender,
education, and APOE, higher plasma tau was associated
with worse memory performance and abnormal cortical
thickness in an AD signature region, highlighting the
potential of plasma tau as a valid neurodegeneration
biomarker in AD [15]. Moreover, higher levels of plasma
tau, examined as a continuous variable, were associated
with significant declines in global cognition, memory, atten-
tion, and visuospatial ability over a median follow-up of
3.0 years and with greater decline in both visuospatial ability
and global cognition at 15 months in mild cognitive impair-
ment patients [16]. Plasma tau was also negatively correlated
with gray matter density in the medial temporal lobe, precu-
neus, thalamus, and striatum [14]. We are aware that
elevated tau alone, both in plasma and CSF, cannot be
considered a specific biomarker for AD. Elevated tau levels
have also been related to traumatic brain injury and postcon-
cussive cognitive symptoms in both acute [19,40] and
chronic traumatic brain injury [41] and to the effect of anes-
thesia and surgery [42]. This body of work highlights the po-
tential validity of plasma tau as a measure of
neurodegeneration, in agreement with our current data,
which demonstrate a negative correlation between plasma
tau and cognitive function (PARD).
Our study reports the interesting and novel finding that,
when combining plasma tau with CSF total tau or CSF P-
tau, the accuracy for the differentiation of AD versus NL
increases, suggesting that plasma tau may be a useful
biomarker to add to CSF tau, and to the AD-specific
CSF P-tau, in AD panels to increase diagnostic power
and determinations of therapeutic efficacy. Plasma tau
may also be useful in addition to other blood biomarkers
of neurodegeneration such as neurofilament light [35,43],
to better determine cognitive improvements in clinical
trials. The possibility of adding measures of plasma or
serum P-tau would also be an important future
development for the field. Multiple assays are under
development with Simoa, MSD [18], and other platforms
[44] to achieve this scope, although not yet commercially
available.
Future clinical studies should focus on confirming if
combining plasma and CSF tau determinations is feasible
and beneficial in terms of costs versus gain.
Overall, this study adds to the current literature in sug-
gesting that plasma tau could represent a valuable biomarker
to include in panels for AD clinical studies in addition
to CSF biomarkers. More research is needed to better
understand the molecular pathways responsible for the
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and CSF, the relationship between plasma and CSF tau mea-
sures, and their association with cognitive dysfunction and
blood brain barrier permeability measures.
The main limitations of our study are a lower number of
subjects in the AD cohort compared with NL controls, the
lack of a mild cognitive impairment cohort, and the fact
that the diagnosis of AD is done by clinical evaluation and
MRI without positron emission tomography or CSF
biomarker confirmation.
Future studies are encouraged to replicate the results from
this report using larger sample sizes and including mild
cognitive impairment or preclinical AD cases, as well as in
longitudinal studies or clinical trials.5. Conclusions
We report that plasma tau discriminates NL controls from
patients with AD with similar AUCs compared with CSF tau
and P-tau and is associated with cognitive measures. We
observe a lack of correlation of plasma tau with CSF tau,
possibly due to the differential influence of tau clearance
and metabolism, as well as other possible sources of tau
contributing to the plasma pool. Importantly, we detect an
increase in the ability to discriminate patients with AD and
NL controls when adding plasma tau to either CSF tau or
CSF P-tau measures, suggesting that including plasma tau
determinations in addition to CSF tau in AD studies could
improve accuracy of diagnosis and detection of therapeutic
effects in clinical trials.Acknowledgments
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1. Systematic review: Novel technologies over the last
few years have enabled the detection of tau in the
blood. Articles related to the development of plasma
tau assays and their relationship with CSF tau mea-
sures were searched on PubMed, and contributed to
the development of our study.
2. Interpretation: This study contributes to the field
showing that plasma tau classifies cognitively normal
controls and patients with Alzheimer’s disease with
similar accuracy when compared with the current
gold-standard cerebrospinal fluid (CSF) tau or CSF
P-tau. Our data corroborates a lack of correlation be-
tween plasma and CSF tau, suggesting that plasma
tau is independent and likely complementary to
CSF tau measures. Importantly, this study reports
the novel finding that adding plasma tau to CSF tau
or CSF P-tau measures increases the accuracy of
the differentiation of patients with AD versus cogni-
tively normal controls.
3. Future directions: Future studies are encouraged to
replicate the results from this report using larger sam-
ple sizes, as well as longitudinal studies, to confirm
that including plasma tau in addition to CSF tau in
AD studies will improve accuracy of diagnosis and
detection of therapeutic effects.References
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